Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Journal
The Lancet. Haematology
ISSN: 2352-3026
Titre abrégé: Lancet Haematol
Pays: England
ID NLM: 101643584
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
21
06
2019
revised:
03
09
2019
accepted:
04
09
2019
pubmed:
9
11
2019
medline:
4
1
2020
entrez:
9
11
2019
Statut:
ppublish
Résumé
Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism. In a multicentre, parallel-group, open-label, randomised study, children (aged 0-17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≥1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed. From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87-95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29-35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11-1·41). Repeat imaging showed an improved effect of rivaroxaban on thrombotic burden as compared with standard anticoagulants (p=0·012). Major or clinically relevant non-major bleeding in participants who received ≥1 dose occurred in ten (3%) of 329 children (all non-major) receiving rivaroxaban and in three (2%) of 162 children (two major and one non-major) receiving standard anticoagulants (HR 1·58, 95% CI 0·51-6·27). Absolute and relative efficacy and safety estimates of rivaroxaban versus standard anticoagulation estimates were similar to those in rivaroxaban studies in adults. There were no treatment-related deaths. In children with acute venous thromboembolism, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants. Bayer AG and Janssen Research & Development.
Sections du résumé
BACKGROUND
BACKGROUND
Treatment of venous thromboembolism in children is based on data obtained in adults with little direct documentation of its efficacy and safety in children. The aim of our study was to compare the efficacy and safety of rivaroxaban versus standard anticoagulants in children with venous thromboembolism.
METHODS
METHODS
In a multicentre, parallel-group, open-label, randomised study, children (aged 0-17 years) attending 107 paediatric hospitals in 28 countries with documented acute venous thromboembolism who had started heparinisation were assigned (2:1) to bodyweight-adjusted rivaroxaban (tablets or suspension) in a 20-mg equivalent dose or standard anticoagulants (heparin or switched to vitamin K antagonist). Randomisation was stratified by age and venous thromboembolism site. The main treatment period was 3 months (1 month in children <2 years of age with catheter-related venous thromboembolism). The primary efficacy outcome, symptomatic recurrent venous thromboembolism (assessed by intention-to-treat), and the principal safety outcome, major or clinically relevant non-major bleeding (assessed in participants who received ≥1 dose), were centrally assessed by investigators who were unaware of treatment assignment. Repeat imaging was obtained at the end of the main treatment period and compared with baseline imaging tests. This trial is registered with ClinicalTrials.gov, number NCT02234843 and has been completed.
FINDINGS
RESULTS
From Nov 14, 2014, to Sept 28, 2018, 500 (96%) of the 520 children screened for eligibility were enrolled. After a median follow-up of 91 days (IQR 87-95) in children who had a study treatment period of 3 months (n=463) and 31 days (IQR 29-35) in children who had a study treatment period of 1 month (n=37), symptomatic recurrent venous thromboembolism occurred in four (1%) of 335 children receiving rivaroxaban and five (3%) of 165 receiving standard anticoagulants (hazard ratio [HR] 0·40, 95% CI 0·11-1·41). Repeat imaging showed an improved effect of rivaroxaban on thrombotic burden as compared with standard anticoagulants (p=0·012). Major or clinically relevant non-major bleeding in participants who received ≥1 dose occurred in ten (3%) of 329 children (all non-major) receiving rivaroxaban and in three (2%) of 162 children (two major and one non-major) receiving standard anticoagulants (HR 1·58, 95% CI 0·51-6·27). Absolute and relative efficacy and safety estimates of rivaroxaban versus standard anticoagulation estimates were similar to those in rivaroxaban studies in adults. There were no treatment-related deaths.
INTERPRETATION
CONCLUSIONS
In children with acute venous thromboembolism, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased bleeding, as compared with standard anticoagulants.
FUNDING
BACKGROUND
Bayer AG and Janssen Research & Development.
Identifiants
pubmed: 31699660
pii: S2352-3026(19)30219-4
doi: 10.1016/S2352-3026(19)30219-4
pii:
doi:
Substances chimiques
Anticoagulants
0
Rivaroxaban
9NDF7JZ4M3
Banques de données
ClinicalTrials.gov
['NCT02234843']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18-e27Investigateurs
Angelo C Molinari
(AC)
Ulrike Nowak Göttl
(U)
Juan Chain
(J)
Jeremy Robertson
(J)
Katharina Thom
(K)
Werner Streif
(W)
Rudolf Schwarz
(R)
Klaus Schmitt
(K)
Gernot Grangl
(G)
An Van Damme
(A)
Philip Maes
(P)
Veerle Labarque
(V)
Antonio Petrilli
(A)
Sandra Loggeto
(S)
Estela Azeka
(E)
Leonardo Brandao
(L)
Doan Le
(D)
Christine Sabapathy
(C)
Paola Giordano
(P)
Runhui Wu
(R)
Jie Ding
(J)
Wenyan Huang
(W)
Jianhua Mao
(J)
Päivi Lähteenmäki
(P)
Pascal Amedro
(P)
Stephane Decramer
(S)
Toralf Bernig
(T)
Martin Chada
(M)
Godfrey Chan
(G)
Krisztian Kally
(K)
Beatrice Nolan
(B)
Shoshana Revel-Vilk
(S)
Hannah Tamary
(H)
Carina Levin
(C)
Daniela Tormene
(D)
Maria Abbattista
(M)
Andrea Artoni
(A)
Takanari Ikeyama
(T)
Ryo Inuzuka
(R)
Satoshi Yasukochi
(S)
Michelle Morales Soto
(M)
Karina A Solis Labastida
(KA)
Monique H Suijker
(MH)
Marike Bartels
(M)
Rienk Y Tamminga
(RY)
C Heleen Van Ommen
(CH)
D Maroeska Te Loo
(DM)
Rui Anjos
(R)
Lyudmila Zubarovskaya
(L)
Natalia Popova
(N)
Elena Samochatova
(E)
Margarita Belogurova
(M)
Pavel Svirin
(P)
Tatiana Shutova
(T)
Vladimir Lebedev
(V)
Olga Barbarash
(O)
Pei L Koh
(PL)
Joyce C Mei
(JC)
Ludmila Podracka
(L)
Ruben Berrueco
(R)
Maria F Fernandez
(MF)
Tony Frisk
(T)
Sebastian Grunt
(S)
Johannes Rischewski
(J)
Manuela Albisetti-Pedroni
(M)
Ali Antmen
(A)
Huseyin Tokgoz
(H)
Zeynep Karakas
(Z)
Elizabeth Chalmers
(E)
Jayashree Motwani
(J)
Michael Williams
(M)
John Grainger
(J)
Jeanette Payne
(J)
Mike Richards
(M)
Susan Baird
(S)
Neha Bhatnagar
(N)
Angela Aramburo
(A)
Shelley Crary
(S)
Tung Wynn
(T)
Shannon Carpenter
(S)
Kerry Hege
(K)
Sanjay Ahuja
(S)
Neil Goldenberg
(N)
Gary Woods
(G)
Kamar Godder
(K)
Ajovi Scott-Emuakpor
(A)
Gavin Roach
(G)
Leslie Raffini
(L)
Nirmish Shah
(N)
Sanjay Shah
(S)
Courtney Thornburg
(C)
Ayesha Zia
(A)
Roger Berkow
(R)
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.